Archon Biosciences

• 31/10/2024
• Seed
• $20,000,000

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease.

We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Archon Biosciences is based in Seattle and supported by a team of forward-thinking investors led by Madrona Ventures. Our AbC platform was invented with the science and technology recognized by the 2024 Nobel Prize in Chemistry at the Baker Lab in the Institute for Protein Design (IPD).

If you are interested in partnering or see yourself as part of our mission, please contact us at contact@archon.bio.

---

---